Heron Therapeutics, Inc.

Symbol: HRTX

NASDAQ

2.94

USD

Market price today

  • -5.4913

    P/E Ratio

  • 0.0418

    PEG Ratio

  • 442.87M

    MRK Cap

  • 0.00%

    DIV Yield

Heron Therapeutics, Inc. (HRTX) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.57%

Operating Profit Margin

-0.62%

Net Profit Margin

-0.61%

Return on Assets

-0.37%

Return on Equity

2.40%

Return on Capital Employed

-0.58%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Craig Alexander Collard
Full-time employees:126
City:San Diego
Address:4242 Campus Point Court
IPO:1987-08-26
CIK:0000818033

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

General Outlook

When we look at how much money they make before expenses, they keep 0.571% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.623%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.613%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.372% return, is a testament to Heron Therapeutics, Inc.'s adeptness in optimizing resource deployment. Heron Therapeutics, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 2.402%. Furthermore, the proficiency of Heron Therapeutics, Inc. in capital utilization is underscored by a remarkable -0.578% return on capital employed.

Stock Prices

Heron Therapeutics, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.49, while its low point bottomed out at $2.32. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Heron Therapeutics, Inc.'s stock market.

Liquidity Ratios

Analyzing HRTX liquidity ratios reveals its financial health of the firm. The current ratio of 246.63% gauges short-term asset coverage for liabilities. The quick ratio (181.55%) assesses immediate liquidity, while the cash ratio (27.13%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio246.63%
Quick Ratio181.55%
Cash Ratio27.13%

Profitability Ratios

HRTX profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -61.28% underscores its earnings before tax deductions. The effective tax rate stands at -0.36%, revealing its tax efficiency. The net income per EBT, 100.00%, and the EBT per EBIT, 98.30%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -62.34%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-61.28%
Effective Tax Rate-0.36%
Net Income per EBT100.00%
EBT per EBIT98.30%
EBIT per Revenue-62.34%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 2.47, it details the span from stock purchase to revenue. The 2 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding182
Days of Inventory Outstanding273
Operating Cycle453.93
Days of Payables Outstanding5
Cash Conversion Cycle449
Receivables Turnover2.02
Payables Turnover67.74
Inventory Turnover1.33
Fixed Asset Turnover5.48
Asset Turnover0.61

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.29, and free cash flow per share, -0.30, depict cash generation on a per-share basis. The cash per share value, 0.47, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.33, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.29
Free Cash Flow per Share-0.30
Cash per Share0.47
Operating Cash Flow Sales Ratio-0.33
Free Cash Flow to Operating Cash Flow Ratio1.03
Cash Flow Coverage Ratio-0.25
Short Term Coverage Ratio-13.84
Capital Expenditure Coverage Ratio-32.86
Dividend Paid and Capex Coverage Ratio-32.86

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 81.29%, highlights its total liabilities relative to assets. With a debt-equity ratio of -5.25, we discern the balance between debt and equity financing. The long-term debt to capitalization, 124.08%, and total debt to capitalization, 123.55%, ratios shed light on its capital structure. An interest coverage of -25.00 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio81.29%
Debt Equity Ratio-5.25
Long Term Debt to Capitalization124.08%
Total Debt to Capitalization123.55%
Interest Coverage-25.00
Cash Flow to Debt Ratio-0.25
Company Equity Multiplier-6.45

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.92, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.80, reflects the portion of profit attributed to each share. The book value per share, -0.25, represents the net asset value distributed per share, while the tangible book value per share, -0.25, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.92
Net Income Per Share-0.80
Book Value Per Share-0.25
Tangible Book Value Per Share-0.25
Shareholders Equity Per Share-0.25
Interest Debt Per Share1.31
Capex Per Share-0.01

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 17.99%, indicates top-line expansion, while the gross profit growth, 17.31%, reveals profitability trends. EBIT growth, 36.67%, and operating income growth, 36.67%, offer insights into operational profitability progression. The net income growth, 17.81%, showcases bottom-line expansion, and the EPS growth, 35.48%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth17.99%
Gross Profit Growth17.31%
EBIT Growth36.67%
Operating Income Growth36.67%
Net Income Growth17.81%
EPS Growth35.48%
EPS Diluted Growth35.48%
Weighted Average Shares Growth26.87%
Weighted Average Shares Diluted Growth26.87%
Operating Cash Flow Growth59.98%
Free Cash Flow Growth59.44%
5-Year Revenue Growth per Share-13.11%
3-Year Revenue Growth per Share-5.81%
10-Year Operating CF Growth per Share83.12%
5-Year Operating CF Growth per Share83.76%
3-Year Operating CF Growth per Share79.10%
10-Year Net Income Growth per Share76.60%
5-Year Net Income Growth per Share67.24%
3-Year Net Income Growth per Share67.63%
10-Year Shareholders Equity Growth per Share-105.77%
5-Year Shareholders Equity Growth per Share-104.86%
3-Year Shareholders Equity Growth per Share-109.44%
Receivables Growth15.54%
Inventory Growth-22.84%
Asset Growth-11.33%
Book Value per Share Growth-297.30%
Debt Growth14.07%
R&D Expense Growth-48.01%
SGA Expenses Growth-2.75%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 385,780,500, captures the company's total value, considering both debt and equity. Income quality, 0.53, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.39, gauges operational efficiency, while the research and development to revenue, 44.00%, highlights investment in innovation.

cards.indicatorcards.value
Enterprise Value385,780,500
Income Quality0.53
Sales General and Administrative to Revenue0.39
Research and Development to Revenue44.00%
Capex to Operating Cash Flow2.63%
Capex to Revenue-1.22%
Capex to Depreciation-53.29%
Stock-Based Compensation to Revenue25.86%
Graham Number2.10
Return on Tangible Assets-49.69%
Graham Net Net-0.80
Working Capital109,089,000
Tangible Asset Value-33,972,999
Net Current Asset Value-67,704,999
Invested Capital-5
Average Receivables56,093,000
Average Payables3,232,500
Average Inventory48,341,500
Days Sales Outstanding173
Days Payables Outstanding18
Days of Inventory On Hand236
ROIC-77.43%
ROE3.25%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -13.16, and the price to book ratio, -13.16, reflect the market's valuation relative to the company's book value. The price to sales ratio, 3.35, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -9.90, and price to operating cash flows, -10.24, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-13.16
Price to Book Ratio-13.16
Price to Sales Ratio3.35
Price Cash Flow Ratio-10.24
Price Earnings to Growth Ratio0.04
Enterprise Value Multiple-3.58
Price Fair Value-13.16
Price to Operating Cash Flow Ratio-10.24
Price to Free Cash Flows Ratio-9.90
Price to Tangible Book Ratio-6.91
Enterprise Value to Sales3.04
Enterprise Value Over EBITDA-3.58
EV to Operating Cash Flow-6.56
Earnings Yield-47.08%
Free Cash Flow Yield-25.69%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Heron Therapeutics, Inc. (HRTX) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -5.491 in 2024.

What is the ticker symbol of Heron Therapeutics, Inc. stock?

The ticker symbol of Heron Therapeutics, Inc. stock is HRTX.

What is company IPO date?

IPO date of Heron Therapeutics, Inc. is 1987-08-26.

What is company current share price?

Current share price is 2.940 USD.

What is stock market cap today?

The market cap of stock today is 442872780.000.

What is PEG ratio in 2024?

The current 0.042 is 0.042 in 2024.

What is the number of employees in 2024?

In 2024 the company has 126.